Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022
Research

High-Dose Convalescent Plasma for Treatment of Severe COVID-19

Gil C. De SantisComments to Author , Luciana Correa Oliveira, Pedro M.M. Garibaldi, Carlos E.L. Almado, Julio Croda, Ghislaine G.A. Arcanjo, Érika A.F. Oliveira, Adriana C. Tonacio, Dante M. Langhi, José O. Bordin, Renato N. Gilio, Leonardo C. Palma, Elaine V. Santos, Simone K. Haddad, Benedito P.A. Prado, Marjorie Cornejo Pontelli, Rogério Gomes, Carlos H. Miranda, Maria Auxiliadora Martins, Dimas T. Covas, Eurico Arruda, Benedito A.L. Fonseca, and Rodrigo T. Calado
Author affiliations: University of São Paulo, São Paulo, Brazil (G.C. De Santis, L.C. Oliveira, E.V. Santos, S.K. Haddad, B.P.A. Prado Jr., D.T. Covas, R.T. Calado); Hospital Estadual de Serrana, Serrana, Brazil (P.M.M. Garibaldi, C.E.L. Almado); Hospital Regional do Mato Grosso do Sul, Campo Grande, Brazil (J. Croda); Fundação Oswaldo Cruz, Campo Grande (J. Croda); Universidade do Mato Grosso do Sul, Campo Grande (J. Croda, G.G.A. Arcanjo); Hospital São Camilo, São Paulo (É.A.F. Oliveira, A.C. Tonacio, D.M. Langhi Jr.); Universidade Federal de São Paulo, São Paulo (D.M. Langhi Jr., J.O. Bordin); Hospital Estadual de Américo Brasiliense, Américo Brasiliense, Brazil (R.N. Gilio); Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil (L.C. Palma); Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, São Paulo (M.C. Pontelli, R. Gomes, C.H. Miranda, M.A. Martins, E. Arruda, B.A.L. Fonseca)

Main Article

Table 2

Clinical outcomes for participants in study of high-dose convalescent plasma for treatment of severe COVID-19, Brazil*

Outcome CCP, n = 36 Control, n = 71 p value
Death at HD 30, no. (%) 8 (22.22) 18 (25.35) 0.81
Death at HD 60, no. (%)
 11 (30.55)
 25 (35.21)
 0.67
Ventilator-free days at HD 30† 12.5 (0–30) 12.0 (0–30) 0.82
Ventilator-free days at HD 60‡
 42.5 (0–60)
 39.0 (0–60)
 0.80
Hospital-free days at HD 30† 3 (0–24) 0 (0–28) 0.27
Hospital-free days at HD 60§ 30.5 (0–53) 21.0 (0–58) 0.45

*CCP, COVID-19 convalescent plasma; COVID-19, coronavirus disease; HD, hospitalization day. †35 CCP and 70 control samples. ‡33 CCP and 67 control samples. §33 CCP and 69 control samples.

Main Article

Page created: January 26, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external